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JOINT LUBRICATION: HOW DOES NATURE DO IT?
J. Klein. Weizmann Inst. of Sci., Rehovot, Israel
The articular cartilage layers coating the major synovial joints such as
hips or knees are remarkable constructs. They not only support a wide
range of stresses and impacts but, inparticular, healthy cartilage surfaces
sliding past each other exhibit extremely low levels of friction under
physiologically-high pressures. This is a lubricity which no man-made
surfaces can emulate. A detailed molecular-level understanding of this
could beneﬁt treatments of osteoarthritis (OA), as well as improved
prosthetic joint implants, where low friction may suppress wear debris
formation and the associated periprosthetic osteolysis. The relation of
cartilage friction to OA development is especially intriguing: while tra-
ditionallyOAwas considereda ‘wearand tear’disease, there is increasing
evidence that protease production by chondrocytes within the cartilage
in response to shear stresses may play an important role in the cartilage
degradation and progress of OA. Since such shear stresses are a direct
consequence of friction on the articulating cartilage surface, it is clear
that insight into ‘how nature does it’ would be of considerable value in
manipulating the friction. But despite decades of study, such under-
standing remains elusive. Any insightmust, ﬁrst and foremost, be able to
account for the low friction (CoF down to ca. 0.001) at the high pressures
(which can reach 100 atm or higher) of the joints. Hydrodynamic effects
have been considered as a lubrication mechanism, but it is likely that a
mixed regime including both ﬂuid-ﬁlm and boundary lubrication
operates, and the crucial issue concerns the nature of the boundary layer
at the cartilage surface. Three quite different components of articular
cartilage and of the synovial ﬂuid surrounding it have each, separately,
been widely invoked as the boundary molecule responsible for the
remarkable lubrication of joints: Hyaluronan (HA), a linear poly-
saccharide; lubricin a proteoglycan; and phospholipids. Direct meas-
urements, however, indicate that none of these can, by itself, explain the
low friction of the cartilage surface at the high pressures characteristic of
the major joints. Over the past decade, hydration lubrication has
emerged as a newparadigm for extreme lubrication in aqueous systems,
which may underlie also the very efﬁcient boundary lubrication of car-
tilage. According to this, the hydration shells formed by dipolar water
molecules about charges in water (such as ions or zwitterions) may be
very tenaciously attached, so that they resist being squeezed out even
under large pressures. At the same time, these same hydration shells
maybehaveveryﬂuidlyunder shear. This resistance topressure together
with low-friction sliding makes them into excellent lubrication ele-
ments. Very recently, we discovered that HA which is attached to a
surface - to resemble its conﬁguration at the outer cartilage surface -may
complex with phosphatidylcholines (PCs), lipids that are ubiquitous in
synovial joints, to form robust boundary layers. These layers act syn-
ergistically to provide the very low friction (mz 0.001) characteristic of
cartilage, at the highest physiological pressures, and contrast with sur-
face-attachedHAon its own,which leads to considerably higher friction.
The very low friction is ultimately due to the phosphocholine groups
exposed by the HA/PC surface complexes; these groups are known to be
strongly and highly-hydrated, and so they lubricate via the mechanism
described above. Our results thus point to a scenario where HA, PCs and1063-4584/$ e see front matterlubricin, each with a very different role, act together synergistically to
reduce frictionof cartilage in articulating joints. Hyaluronan, anchored at
the outer surface of articular cartilage by lubricin molecules (which are
known to be present in the outer superﬁcial zone), complexes with joint
phosphatidylcholines to provide the extreme boundary lubrication of
synovial joints via the hydration-lubrication mechanism.
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LUBRICIN AND ITS POTENTIAL AS AN OA THERAPY
C.R. Flannery. Genzyme, a Sanoﬁ Company, Framingham, MA, USA
Originally identiﬁed as a lubricating component of synovial ﬂuid, the
mucinous glycoprotein lubricin is now recognized to be a major chon-
droprotective macromolecule which localizes to, and affords boundary
lubrication of, articular cartilage surfaces. Lubricin is synthesized in the
joint by cells of the synovial lining, as well as by tendon and meniscal
cells, in addition to its expression by superﬁcial zone chondrocytes
(wherefrom it was initially described as ‘superﬁcial zone protein’, or
SZP). Genetic ablation of lubricin synthesis in mice, or in humans with a
rare autosomal recessive disorder, CACP syndrome, results in accel-
erated cartilage damage and joint failure, with associated non-inﬂam-
matory synovial hypercellularity/thickening and subintimal capsular
ﬁbrosis. In addition, data from joint injury models have demonstrated
alterations in lubricin expression, as well as elevated cartilage friction
levels which may be attenuated by lubricin restitution.
Based in part on the aforementioned ﬁndings, several independent
laboratories have explored the potential utility of lubricin supple-
mentation for the treatment of OA. Such investigations have included
augmentation via intraarticular injections of natural or recombinant
lubricin molecules, and these campaigns have been successful in pre-
clinical (rodent) models of OA, resulting in reduced cartilage damage
and OA scores. Additional beneﬁcial consequences of lubricin admin-
istration have also been demonstrated, including protection against
chondrocyte apoptosis, and evidence for symptom (pain) modiﬁcation
as measured by normalization of differential weight-bearing, or gait
asymmetry, between diseased and contralateral limbs.
An important consideration for such therapeutic strategies relates to
the ‘residence time’ of exogenously applied lubricin within the joint.
Whereas soluble molecules present in synovial ﬂuid exhibit a relatively
rapid rate of clearance, lubricin bound to tissue (i.e. cartilage) surfaces
can exhibit a greater longevity, and maximizing lubricin retention and
exposure within the joint would seem to bear high importance for
successful translational applicability. In this regard, other opportunities
for providing enduring lubricin levels may include gene therapy-based
approaches wherein lubricin is delivered via, for example, viral-based
vectors, and for which preclinical proof-of-principle studies have also
recently been reported.
The ultimate clinical development of lubricin supplementation thera-
pies will be dependent on a number of critical factors. Of high impor-
tance is the technical capability and capacity to produce validated and
cost-effective materials (i.e. recombinant lubricin molecules). Equally
necessary are contingencies for identifying a responsive patient pop-
ulation, and establishing appropriate, clinically meaningful and regu-
latory agency-approved endpoints which can be robustly measured. As
